A 3 ml Ozempic (semaglutide) pen sold in mainland China. Photo: HualinXMN, CC BY-SA 4.0 (via Wikimedia Commons); cropped and resized. File image of a medicine in the GLP-1 class; the FDA action applies to the class, not only this product.
Lifestyle · 07:25
FDA warns of rare eye-condition risk with GLP-1 drugs
The U.S. Food and Drug Administration is requiring a safety-labeling change for all marketed GLP-1 medicines after concluding there is a potential increased risk of a rare eye condition, NAION. A causal relationship has not been settled.